Two melanoma treatments approved for PBS listing
24 December 2019
In a boost for melanoma patients across Australia, the Federal Government’s PBAC has recommended subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients. Two melanoma treatments are recommended by the PBAC for PBS listing - nivolumab for resected Stage III/IV (high risk) metastatic melanoma, and the combination ipilimumab and nivolumab as first-line therapy for Stage IV (advanced) melanoma.
Co-Medical Directors of Melanoma Institute Australia, Professor Georgina Long and Professor Richard Scolyer, said providing subsidised access to these treatments was wonderful news for melanoma patients and their families around Australia, as until now, they could only access these treatments through clinical trials or on compassionate grounds, or face costs of tens of thousands of dollars.
‘Our clinical trials have proven nivolumab is effective in preventing melanoma recurrence and its spread to other organs including the brain, lungs and liver in the majority of high risk resected Stage III patients,’ said Professor Georgina Long. ‘Our trials have also proven the effectiveness of the combination immunotherapy as front line treatment for Stage IV melanoma patients where their disease has already spread to other organs, including the brain.’
‘Providing certainty of access to these treatments via the PBS will be life-changing and life-saving, and we applaud the Federal Government for this decision,’ added Professor Richard Scolyer.
Shown in photo: Melanoma Institute Australia's Co-Medical Directors - Professor Georgina Long and Professor Richard Scolyer
Next Steps for National Screening Program for Melanoma
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March Update
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Saving lives this summer: 'Game On Mole!'
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
PBS boost for melanoma patients
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
An open letter to all young Australians
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
MIA leads world-class skin tumour pathology conference
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
MAFS, it is time for a reality check on solariums.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.
Community Fundraising January Wrap-Up
Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.
Kyly Clarke urges Aussies to step up to save lives from melanoma
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Improving support for our patients across Australia.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Boost to melanoma support in WA
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
New Test to Predict Primary Melanoma Progression
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
Community Fundraising December Wrap-Up
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Two melanoma treatments approved for PBS listing
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
Immunotherapy: the decade's biggest health advance
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Boost to Melanoma Services in the Riverina
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Winner of the SunSafe Student Ambassador Program announced
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
Community Fundraising November Wrap-Up
It’s time again to say thank you to our amazing community fundraisers!
MIA & MPA Patient Information Evening videos now available
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA shines in poster session
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.